RV-PA uncoupling is associated with increased mortality in transthyretin amyloid cardiomyopathy treated with tafamidis

被引:0
|
作者
Schwarting, Stephanie K. [1 ,2 ]
Poledniczek, Michael [2 ,3 ]
Metodiev, Yuliyan [1 ]
Stolz, Lukas [1 ]
Hofmann, Eva [2 ]
Hegenbart, Ute [4 ]
Schoenland, Stefan [4 ]
Kaeaeb, Stefan [1 ,5 ]
Massberg, Steffen [1 ]
Frey, Norbert [2 ]
Aus Dem Siepen, Fabian [2 ]
机构
[1] LMU Univ Hosp Munich, Dept Med 1, Marchionini str 15, D-81377 Munich, Germany
[2] Univ Hosp Heidelberg, Dept Cardiol Angiol & Resp Med, Neuenheimer Feld 410, Heidelberg, Germany
[3] Med Univ Vienna, Dept Internal Med 2, Div Cardiol, Vienna, Austria
[4] Univ Hosp Heidelberg, Dept Internal Medicine5, Neuenheimer Feld 410, Heidelberg, Germany
[5] European Reference Network Rare Low Prevalence & C, Amsterdam, Netherlands
关键词
RV-PA coupling; Amyloidosis; Transthyretin; Echocardiography; TAPSE/PASP-ratio; HEART-FAILURE; CLINICAL-OUTCOMES; PROGNOSTIC VALUE; REPAIR; IMPACT;
D O I
10.1007/s00392-024-02576-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The right ventricle to pulmonary artery coupling (RV-PAc) describes the right ventricle's ability to adjust to an increased afterload. In case of transthyretin amyloid cardiomyopathy (ATTR-CM), impaired RV-PAc can result from increased left ventricular diastolic stiffness due to fibril deposition. Objectives While RV-PAc is a validated prognostic parameter in pulmonary arterial hypertension (PAH), its prognostic relevance in ATTR-CM remains unknown. We sought to evaluate the prognostic implications of impaired RV-PAc on survival in ATTR-CM. Methods In this multicentre study, RV-PAc was investigated by the echocardiographic surrogate of ratio of tricuspid annular plane systolic excursion to estimated pulmonary arterial systolic pressure (TAPSE/PASP) in 418 ATTR-CM patients, all treated with a TTR stabilizer. The primary outcome was all-cause mortality. Results Within a median time of 1.52 [IQR 0.72-2.56] years after diagnosis, 49 (11.7%) patients died. In multivariate Cox regression analysis impaired RV-PAc was a strong independent predictor of mortality (Hazard Ratio (HR) 2.16, 95% Confidence Interval (CI) 1.14-4.07, p = 0.018). RV-PAc ratio at first presentation emerged as a robust marker for risk stratification with a determined optimal cut-off of 0.382 mm/mmHg (area under the curve (AUC) 0.73, 95% CI 0.65-0.81). Patients with RV-PAc ratio <= 0.382 mm/mmHg exhibited significantly lower survival (HR 4.17, 95% CI 2.21-7.87, p < 0.001) within 3 years of follow up than those with RV-PAc ratio above the cut-off (Graphical Abstract). Conclusion Impaired adaptation of the RV to increased afterload is associated with worse outcome in ATTR-CM patients. RV-PAc ratio can serve as an echocardiographic predictor for all-cause mortality. Therefore, the determination of RV-PAc could improve risk stratification for ATTR-CM patients.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] RV-PA uncoupling is a strong predictor of mortality in transthyretin amyloid cardiomyopathy
    Schwarting, Stephanie
    Poledniczek, Michael
    Hofmann, Eva
    Frey, Norbert
    Kaab, Stefan
    Hegenbart, Ute
    Schoenland, Stefan
    Siepend, Fabian Aus Dem
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 : S52 - S52
  • [2] RV-PA uncoupling is a strong predictor of 3-year all-cause mortality in transthyretin amyloid cardiomyopathy
    Schwarting, S.
    Poledniczek, M.
    Metodiev, Y.
    Stolz, L.
    Hofmann, E.
    Hegenbart, U.
    Schoenland, S.
    Kaeaeb, S.
    Massberg, S.
    Frey, N.
    Siepen, F. Aus Dem
    EUROPEAN HEART JOURNAL, 2024, 45
  • [4] Outcomes of Octogenarian Patients Treated with Tafamidis for Transthyretin Amyloid Cardiomyopathy
    Sarkar, Abdullah
    Sanchez-Nadales, Alejandro
    Kunutsor, Setor K.
    Hanna, Mazen A.
    Asher, Craig R.
    Wolinsky, David G.
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 214 : 144 - 148
  • [5] Mortality Among Older Transthyretin Amyloid Cardiomyopathy Patients On Tafamidis
    Batra, Supria
    Patel, Hina
    Govi, Ashley
    Panjrath, Gurusher
    JOURNAL OF CARDIAC FAILURE, 2025, 31 (01)
  • [6] Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy
    Lamb, Yvette N.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2021, 21 (01) : 113 - 121
  • [7] Tafamidis for Transthyretin Amyloid Cardiomyopathy Reply
    Maurer, Mathew S.
    Sultan, Marla B.
    Rapezzi, Claudio
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (02): : 196 - 197
  • [8] Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy
    Yvette N. Lamb
    American Journal of Cardiovascular Drugs, 2021, 21 : 113 - 121
  • [9] Tafamidis (Vyndaqel; Vyndamax) for Transthyretin Amyloid Cardiomyopathy
    Abramowicz, Mark
    Zuccotti, Gianna
    Pflomm, Jean-Marie
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (05): : 505 - 505
  • [10] Tafamidis A Novel Treatment for Transthyretin Amyloid Cardiomyopathy
    Nawarskas, James J.
    Shephard, Emily A.
    CARDIOLOGY IN REVIEW, 2020, 28 (03) : 156 - 160